Akari Therapeutics (AKTX) 6-K27 Sep 222022 Q2 Current report (foreign)Financial data

Company Profile

Document And Entity Information

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2022
Document Information [Line Items]
Document Type	6-K
Document Period End Date	Jun. 30, 2022
Entity Registrant Name	Akari Therapeutics Plc
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001541157
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 8,151,177	$ 9,361,270
Prepaid expenses	3,085,898	2,173,528
Other current assets	115,172	90,301
Total Current Assets	11,352,247	11,625,099
Patent acquisition costs, net	18,844	22,929
Total Assets	11,371,091	11,648,028
Current Liabilities:
Accounts payable	1,634,771	1,788,563
Accrued expenses	1,410,540	3,184,883
Liability related to deposits received for share subscriptions		1,120,000
Total Liabilities	3,045,311	6,093,446
Commitments and Contingencies
Shareholders' Equity:
Share capital of $0.0001 par value Authorized: 15,000,000,000 ordinary shares; issued and outstanding: 5,934,917,123 and 4,759,731,923 at June 30, 2022 and December 31, 2021, respectively	593,492	475,973
Additional paid-in capital	166,721,455	153,130,813
Capital redemption reserve	52,193,811	52,193,811
Accumulated other comprehensive loss	(621,557)	(540,967)
Accumulated deficit	(210,561,421)	(199,705,048)
Total Shareholders' Equity	8,325,780	5,554,582
Total Liabilities and Shareholders' Equity	$ 11,371,091	$ 11,648,028

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	15,000,000,000	15,000,000,000
Common stock, shares issued	5,934,917,123	4,759,731,923
Common stock, shares outstanding	5,934,917,123	4,759,731,923

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - UNAUDITED - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating Expenses:
Research and development expenses	$ 2,851,108	$ 2,183,349	$ 4,990,715	$ 5,712,733
General and administrative expenses	2,965,044	2,146,652	6,069,422	4,165,938
Total Operating Expenses	5,816,152	4,330,001	11,060,137	9,878,671
Loss from Operations	(5,816,152)	(4,330,001)	(11,060,137)	(9,878,671)
Other Income (Expense):
Interest income	3,955	1,515	8,317	5,250
Foreign currency exchange gains (losses)	141,424	(12,754)	211,761	(298,608)
Other expenses	(9,205)	(5,095)	(16,314)	(12,807)
Total Other Income (Expense)	136,174	(16,334)	203,764	(306,165)
Net Loss	(5,679,978)	(4,346,335)	(10,856,373)	(10,184,836)
Other Comprehensive (Loss) Income:
Foreign Currency Translation Adjustment	(48,240)	(78,118)	(80,590)	227,979
Comprehensive Loss	$ (5,728,218)	$ (4,424,453)	$ (10,936,963)	$ (9,956,857)
Loss per ordinary share (basic)	$ 0	$ 0	$ 0	$ 0
Loss per ordinary share (diluted)	$ 0	$ 0	$ 0	$ 0
Weighted average ordinary shares (basic)	5,934,917,123	3,847,352,386	5,648,226,680	3,874,631,250
Weighted average ordinary shares (diluted)	5,934,917,123	3,847,352,386	5,648,226,680	3,874,631,250

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - UNAUDITED - USD ($)	Common Stock	Additional Paid-in Capital	Capital Redemption Reserve.	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Shareholders' Equity at Dec. 31, 2020	$ 384,733	$ 139,734,651	$ 52,193,811	$ (648,065)	$ (182,280,811)	$ 9,384,319
Shareholders' Equity (in shares) at Dec. 31, 2020	3,847,331,923
Stock-based compensation		84,892				84,892
Comprehensive loss				306,097	(5,838,501)	(5,532,404)
Shareholders' Equity at Mar. 31, 2021	$ 384,733	139,819,543	52,193,811	(341,968)	(188,119,312)	3,936,807
Shareholders' Equity (in shares) at Mar. 31, 2021	3,847,331,923
Shareholders' Equity at Dec. 31, 2020	$ 384,733	139,734,651	52,193,811	(648,065)	(182,280,811)	9,384,319
Shareholders' Equity (in shares) at Dec. 31, 2020	3,847,331,923
Comprehensive loss						(9,956,857)
Shareholders' Equity at Jun. 30, 2021	$ 396,498	141,883,409	52,193,811	(420,086)	(192,465,647)	1,587,985
Shareholders' Equity (in shares) at Jun. 30, 2021	3,964,979,023
Shareholders' Equity at Mar. 31, 2021	$ 384,733	139,819,543	52,193,811	(341,968)	(188,119,312)	3,936,807
Shareholders' Equity (in shares) at Mar. 31, 2021	3,847,331,923
Stock-based compensation		82,102				82,102
Issuance of share capital related to financing, net of issuance costs	$ 11,765	1,981,764				1,993,529
Issuance of share capital related to financing, net of issuance costs (in shares)	117,647,100
Comprehensive loss				(78,118)	(4,346,335)	(4,424,453)
Shareholders' Equity at Jun. 30, 2021	$ 396,498	141,883,409	52,193,811	(420,086)	(192,465,647)	1,587,985
Shareholders' Equity (in shares) at Jun. 30, 2021	3,964,979,023
Shareholders' Equity at Dec. 31, 2021	$ 475,973	153,130,813	52,193,811	(540,967)	(199,705,048)	5,554,582
Shareholders' Equity (in shares) at Dec. 31, 2021	4,759,731,923
Stock-based compensation		98,836				98,836
Issuance of share capital related to financing, net of issuance costs	$ 117,519	13,368,950				13,486,469
Issuance of share capital related to financing, net of issuance costs (in shares)	1,175,185,200
Comprehensive loss				(32,350)	(5,176,395)	(5,208,745)
Shareholders' Equity at Mar. 31, 2022	$ 593,492	166,598,599	52,193,811	(573,317)	(204,881,443)	13,931,142
Shareholders' Equity (in shares) at Mar. 31, 2022	5,934,917,123
Shareholders' Equity at Dec. 31, 2021	$ 475,973	153,130,813	52,193,811	(540,967)	(199,705,048)	5,554,582
Shareholders' Equity (in shares) at Dec. 31, 2021	4,759,731,923
Comprehensive loss						(10,936,963)
Shareholders' Equity at Jun. 30, 2022	$ 593,492	166,721,455	52,193,811	(621,557)	(210,561,421)	8,325,780
Shareholders' Equity (in shares) at Jun. 30, 2022	5,934,917,123
Shareholders' Equity at Mar. 31, 2022	$ 593,492	166,598,599	52,193,811	(573,317)	(204,881,443)	13,931,142
Shareholders' Equity (in shares) at Mar. 31, 2022	5,934,917,123
Stock-based compensation		122,856				122,856
Comprehensive loss				(48,240)	(5,679,978)	(5,728,218)
Shareholders' Equity at Jun. 30, 2022	$ 593,492	$ 166,721,455	$ 52,193,811	$ (621,557)	$ (210,561,421)	$ 8,325,780
Shareholders' Equity (in shares) at Jun. 30, 2022	5,934,917,123

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities:
Net loss	$ (10,856,373)	$ (10,184,836)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,948	2,082
Stock-based compensation	221,692	166,994
Foreign currency exchange (gains)/ losses	(136,504)	194,619
(Decrease) increase in liabilities:
Prepaid expenses and other current assets	(933,339)	(490,958)
Accounts payable and accrued expenses	(1,920,765)	(1,971,778)
Total adjustments	(2,766,968)	(2,099,041)
Net Cash Used in Operating Activities	(13,623,341)	(12,283,877)
Cash Flows from Financing Activities:
Net proceeds from issuance of shares	12,366,469	1,993,529
Net Cash Provided by Financing Activities	12,366,469	1,993,529
Effect of Exchange Rates on Cash	46,779	26,157
Net Decrease in Cash	(1,210,093)	(10,264,191)
Cash, beginning of period	9,361,270	14,055,777
Cash, end of period	8,151,177	$ 3,791,586
Supplement cash flow information:
Ordinary Share Subscriptions Deposit received in December 2021	$ 1,120,000

Nature of Business

Nature of Business	6 Months Ended
Nature of Business	Jun. 30, 2022
Nature of Business
Nature of Business	NOTE 1 – Nature of Business Akari Therapeutics, Plc, (the “Company” or “Akari”) is incorporated in the United Kingdom. The Company is a clinical-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways. The Company’s activities since inception have consisted of performing research and development activities and raising capital. The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with the pandemic and the Russian invasion of Ukraine, risks associated with clinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. In addition, the Company is subject to risks related to COVID-19. As of June 30, 2022, the Company has an accumulated deficit of $210,561,421 and cash of $8,151,177 and negative cash flows from operating activities for the six months ended June 30, 2022 in the amount of $13,623,341. On June 30, 2020, the Company entered into a securities purchase agreement (the “2020 Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30,000,000 of the Company’s ADSs over the 30-month term of the Purchase Agreement (See Note 4). As of June 30, 2022, approximately $22,000,000 remains available under the facility. The Company believes its current capital resources are sufficient to support its operations into June 2023. To fund its future capital needs beyond its current cash reach, the Company plans to raise additional funds through equity or debt financings or other sources, such as strategic partnerships, alliance and/or licensing arrangements, and in the long term, proceeds from sales of commercial products For the six months ended June 30, 2022, the Company reported a net loss of $10,856,373 and expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities. To fund its capital needs, the Company plans to raise funds through equity or debt financings or other sources, such as strategic partnerships and alliance and licensing arrangements, and in the long term, from the proceeds from sales of commercial products. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern. NOTE 1 – Nature of Business (cont.) Public health epidemics or outbreaks could adversely impact the Company’s business. The situation surrounding the COVID-19 pandemic, including the mutation of variants, continues to remain fluid globally and the Company continues to manage ongoing challenges associated with the pandemic as they relate to operations. The potential for a material impact on our business, financial condition and results of operation remains a risk. Management cannot reasonably estimate with any degree of certainty any future impact of COVID-19. Pandemics such as this can adversely impact the Company’s business as a result of disruptions, such as travel bans, quarantines, staffing shortages, and interruptions to access the trial sites and supply chains, which could result in material delays and complications with respect to our research and development programs and clinical trials. Moreover, as a result of COVID-19, there is a general unease of conducting certain non-critical activities in medical centers. For example, while now open for enrollment, prior clinical trials have been halted or delayed due to COVID-19. The extent to which COVID-19 impacts operations will depend on future developments, including the scope of any new virus mutations and outbreaks, the nature of government public health guidelines and the public’s adherence to those guidelines, the rate of individuals becoming fully vaccinated and the public’s adherence to guidelines to receive booster vaccinations, and the extent to which new lockdowns may be needed or are required in particular countries, including China. In particular, the continued spread of COVID-19 globally could adversely impact our operations and workforce, including research and clinical trials and the ability to raise capital, could affect the operations of key governmental agencies, such as the FDA, which may delay the development of our product candidates, and could result in the inability of suppliers to deliver components or raw materials, including drug product and drug substance, on a timely basis or at all, each of which in turn could have an adverse impact on our business, financial condition and results of operation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	NOTE 2 – Summary of Significant Accounting Policies Basis of Presentation Principles of Consolidation – Foreign Currency – The reporting currency of the Company is U.S. dollars. The Company translated its non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains/(losses). NOTE 2 – Summary of Significant Accounting Policies (cont.) Use of Estimates – Fair Value Measurements Cash – Prepaid Expenses and Other Current Assets Property and Equipment, net – Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 3 Property and equipment, consists of the following: June 30, December 31, 2022 2021 Computers, peripheral, and scientific equipment $ 85,489 $ 85,489 Office furniture and equipment 79,449 79,449 Total property and equipment 164,938 164,938 Less: Accumulated depreciation (164,938) (164,938) Property and equipment, net $ - $ - The Company did not incur any depreciation expense for the three and six months ended June 30, 2022 and 2021. Long-Lived Assets Patent Acquisition Costs NOTE 2 – Summary of Significant Accounting Policies (cont.) Accrued Expenses Research and Development Expenses – Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations (CROs) and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. Research and development expenses for the three months ended June 30, 2022 and 2021 were $2,851,108 and $2,183,349, respectively. Research and development expenses for the six months ended June 30, 2022 and 2021 were $4,990,715 and $5,712,733, respectively. The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the Consolidated Statements of Comprehensive Loss. Stock-Based Compensation Expense – Compensation - Stock Compensation NOTE 2 – Summary of Significant Accounting Policies (cont.) Leases – Concentration of Credit Risk – Income Taxes The Company accounts for income taxes in accordance with the accounting rules that require an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carryforwards and are measured using the expected tax rates estimated to be in effect when such basis differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized. The Company has recorded a full valuation allowance on its deferred tax assets as of June 30, 2022 and December 31, 2021. Uncertain Tax Positions – Accounting for Uncertainty in Income Taxes Accounting for Uncertainty in Income Taxes NOTE 2 – Summary of Significant Accounting Policies (cont.) Earnings (Loss) Per Share Comprehensive Loss – The following table provides details with respect to changes in accumulated other comprehensive loss, which is comprised of foreign currency translation adjustments, as presented in the balance sheets at June 30, 2022: Balance, January 1, 2022 $ (540,967) Net current period other comprehensive loss (80,590) Balance, June 30, 2022 $ (621,557) Recent Accounting Pronouncements Adopted during the period – In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for convertible instruments by removing major separation models in ASC 470-20 that require separate accounting for embedded conversion features. ASU 2020-06 also removes certain settlement conditions in ASC 815-40 that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the scope exception and simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. Adoption of ASU 2020-06 can either be on a modified retrospective or full retrospective basis. The Company adopted this guidance effective January 1, 2022. The adoption of the guidance did not have a material impact on the consolidated financial statements and related disclosures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2022
Fair Value Measurements
Fair Value Measurements	NOTE 3 – Fair Value Measurements Fair value of financial instruments: The estimated fair value of financial instruments has been determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange. The carrying amounts of cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. NOTE 3 – Fair Value Measurements (cont.) Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, Fair Value Measurements and Disclosures Level 1 - Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of June 30, 2022 and December, 31, 2021, the Company did not have any financial assets that require fair value measurement on a recurring basis.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
Shareholders' Equity	Jun. 30, 2022
Shareholders' Equity
Shareholders' Equity	NOTE 4 – Shareholders’ Equity 2020 Purchase Agreement and Registration Rights Agreement with Aspire Capital – On June 30, 2020, the Company entered into a Purchase Agreement (“2020 Purchase Agreement”) with Aspire Capital, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s ADS, with each ADS representing one hundred (100) ordinary shares, during a 30-month period beginning on the effective date of a registration statement related to the transaction. Concurrently with entering into the 2020 Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital, in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, as amended (the “Securities Act”), the sale of the Company’s securities that have been and may be issued to Aspire Capital under the 2020 Purchase Agreement. Under the 2020 Purchase Agreement, after the SEC declared effective the registration statement referred to above (which occurred in July 2020), on any trading day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 150,000 ADSs per business day and up to $30.0 million of the Company’s ADSs in the aggregate at a per share price (the “Purchase Price”) equal to the lesser of: ● the lowest sale price of the Company’s ADSs on the purchase date; or ● the arithmetic average of the three ( 3 ) lowest closing sale prices for the ADSs during the ten ( 10 ) consecutive business days ending on the business day immediately preceding such Purchase Date (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). NOTE 4 – Shareholders’ Equity (cont.) In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in an amount of 150,000 ADSs, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of ADSs equal to up to 30% of the aggregate shares of the Company’s ADSs traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of 250,000 ADSs. The purchase price per share pursuant to such VWAP Purchase Notice is generally 97% of the volume-weighted average price for the Company’s ADSs traded on its principal market on the VWAP Purchase Date. The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Purchase Agreement, so long as the most recent purchase has been completed. The 2020 Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any purchase date where the closing sale price of the Company’s ADSs is less than $0.25. Additionally, governing law in the United Kingdom, where the Company is incorporated, requires a minimum payment per ADS to be issued pursuant to a purchase notice equal to the nominal value of an ADS (i.e., $0.0001). There are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control the timing and amount of sales of the Company’s ADSs to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In accordance with ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock Derivatives and Hedging. In consideration for entering into the 2020 Purchase Agreement, the Company issued to Aspire Capital 40,760,900 ordinary shares of the Company (the “2020 Commitment Shares”) which had a fair value of approximately $900,000. Since the Company has determined that the 2020 Purchase Agreement was considered a freestanding put option derivative in accordance with ASC 815 Derivatives and Hedging During the twelve months ended December 31, 2020, the Company sold to Aspire Capital 460,758,800 ordinary shares of the Company for gross proceeds of approximately $6,000,000. During the twelve months ended December 31, 2021, the Company sold to Aspire Capital 117,647,100 ordinary shares of the Company for gross proceeds of $2,000,001. As of June 30, 2022, approximately $22 million of the original purchase commitment of $30 million remains available under the facility. NOTE 4 – Shareholders’ Equity (cont.) 2021 Private Placements - December 2021 Registered Direct Offering NOTE 4 – Shareholders’ Equity (cont.) March 2022 Registered Direct Offering Warrants issued in 2021 and 2022 The Company accounts for warrants issued to investors and a placement agent after December 8, 2020 as Additional paid-in capital within Shareholders’ equity on the Consolidated Balance Sheets and measured their fair values at their grant date with no subsequently re-measuring at each reporting period. The Company has determined that, at the time of their issuance, the July 2021 Warrants, the December 2021 Warrants as well as the March 2022 Warrants met the requirements for classification as equity under ASC 815-40-25. The costs directly attributable to realizing proceeds of issuing ADSs such as placement agent fees, commissions, legal and accounting fees pertaining to the financing and other external, incremental fees and expenses paid to advisors are recognized in Additional paid-in capital of the Shareholders’ Equity on the Consolidated Balance Sheets in accordance with ASC 814-40. At July 16, 2021, the fair value of the July 2021 Warrants was $231,063 and was recorded within Additional paid-in capital of Shareholders’ Equity. At January 4, 2022, the fair value of the December 2021 Warrants was $2,605,577 and was recorded within Additional paid-in capital of Shareholders’ Equity. At March 10, 2022, the fair value of the March 2022 Warrants was $3,693,622 and was recorded within Additional paid-in capital of Shareholders’ Equity. Below are the assumptions used for the fair value calculations of the warrants issued in 2021: July 16, 2021 Standard deviation 110.00 % Annual risk-free interest rate 0.79 % Required return on equity 17.00 % Expected life in years 4.98 Annual turnover rate 0.00 % Period risk-free rate 0.07 % NOTE 4 – Shareholders’ Equity (cont.) Below are the assumptions used for the fair value calculations of the warrants issued in 2022: January 4, March 10, 2022 2022 Expected dividend yield 0 % 0 % Expected volatility 110 % 110 % Risk-free interest 1.4 % 1.9 % Expected life 5.0 5.0 Balance Warrants Balance Warrants Balance Exercise December 31, Issued December 31, Issued June 30, Description Price 2020 in 2021 2021 in 2022 2022 2019 Investor Warrants $ 3.00 1,184,213 - 1,184,213 - 1,184,213 2019 Placement Warrants $ 2.85 177,629 - 177,629 - 177,629 2020 Investor Warrants $ 2.20 2,797,636 - 2,797,636 - 2,797,636 2020 Placement Warrants $ 2.55 449,623 - 449,623 - 449,623 July 2021 Placement Agent Warrants $ 2.32 - 398,384 398,384 - 398,384 December 2021 Investor Warrants $ 1.65 - - - 2,155,507 2,155,507 December 2021 Placement Agent Warrants $ 1.75 - - - 172,441 172,441 March 2022 Investor Warrants $ 1.40 - - - 3,720,409 3,720,409 March 2022 Placement Agent Warrants $ 1.50 - - - 297,633 297,633 4,609,101 398,384 5,007,485 6,345,990 11,353,475 Share Based Compensation Share option plan In accordance with the Company’s 2014 Equity Incentive Plan (the “Plan”), the number of shares that may be issued upon exercise of options under the Plan shall not exceed 890,000,000 ordinary shares. At June 30, 2022, 510,188,415 ordinary shares are available for future issuance under the Plan. The option plan is administered by the Company’s Board of Directors and grants are made pursuant thereto by the compensation committee. The per share exercise price for the shares to be issued pursuant to the exercise of an option shall be such price equal to the fair market value of the Company’s ordinary shares on the grant date and set forth in the individual option agreement. Options expire ten years after the grant date and typically vest over one The following is a summary of the Company’s share option activity and related information for employees and directors for the period ended June 30, 2022: Weighted average Weighted Weighted remaining average average contractual Aggregate Number exercise grant date term intrinsic of shares price fair value (in years) value Options outstanding as of January 1, 2022 142,949,035 $ 0.07 6.8 - Changes during the period: Granted 253,134,400 $ 0.01 0.01 9.7 - Forfeited 16,271,850 $ 0.32 0.21 3.2 - Options outstanding at June 30, 2022 379,811,585 $ 0.02 8.7 - Exercisable options at June 30, 2022 93,802,185 $ 0.05 6.2 - NOTE 4 – Shareholders’ Equity (cont.) The Company measures compensation cost for all share-based awards at fair value on the date of grant and recognizes compensation expense in general administrative and research and development expenses within its unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) using the straight-line method over the service period over which it expects the awards to vest. The Company estimates the fair value of all time-vested options as of the date of grant using the Black-Scholes option valuation model, which was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions, including the expected share price volatility, which is calculated based on the historical volatility of peer companies. The Company uses a risk-free interest rate, based on the U.S. Treasury instruments in effect at the time of the grant, for the period comparable to the expected term of the option. Given its limited history with share option grants and exercises, the Company uses the “simplified” method in estimating the expected term, the period of time that options granted are expected to be outstanding, for its grants. The Company classifies its stock-based payments which are settled in ordinary shares as equity-classified awards. The Company measures equity-classified awards at their grant date fair value and does not subsequently re-measure them. Compensation costs related to equity-classified awards generally are equal to the grant date fair value of the award amortized over the vesting period of the award. Estimates of fair values are not intended to predict actual future events or the reasonableness of the original estimates of fair value made by the Company. Below are the assumptions used for the options granted during the six months ended June 30, 2022: June 30, 2022 Expected dividend yield 0 % Expected volatility 72.8 - 90.4 % Risk-free interest 1.5% - 3.1 % Expected life 5.5-6.3 years The following is a summary of the Company’s share options granted separated into ranges of exercise price as of June 30, 2022: Weighted Remaining average Weighted contractual exercise average Weighted life (years price ($ Exercise remaining average for for price Options contractual exercise Options exercisable exercisable (range) ($) outstanding life (years) price ($) exercisable options) options) 0.01 244,634,400 9.7 0.01 - - - 0.02 101,950,000 7.7 0.02 60,575,000 7.1 0.02 0.03-0.05 14,450,000 5.2 0.04 14,450,000 5.2 0.04 0.12-0.32 18,777,185 3.8 0.16 18,777,185 3.8 0.16 379,811,585 93,802,185 Restricted Stock Units Restricted stock units (RSUs) are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is generally delivered on or following satisfaction of vesting conditions. The Company issues RSUs to management that vest solely based on the recipient’s continued service over time, primarily with a two NOTE 4 – Shareholders’ Equity (cont.) The Company estimates the fair value of its time-based RSUs on the date of grant based on the Company’s closing stock price at the time of grant. The following tables summarize the activity of the Company’s unvested RSUs for the six months ended June 30, 2022: Weighted average grant date Intrinsic Shares/ fair value value Units per share per share Outstanding as of January 1, 2022 - - Changes during the period: Granted 21,475,400 $ 0.01 Vested - - Forfeited - - Outstanding at June 30, 2022 21,475,400 $ 253,410 $ 214,754 During the three months ended June 30, 2022 and 2021, the Company recorded approximately $122,856 and $82,102, respectively, in stock-based compensation expenses for employees and directors. During the six months ended June 30, 2022 and 2021, the Company recorded approximately $221,692 and $166,994, respectively, in stock-based compensation expenses for employees and directors. At June 30, 2022, there was approximately $2,619,879 of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s share option plans which the Company expects to recognize over a weighted average of 3.5 years.

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2022
Related Party Transactions
Related Party Transactions	NOTE 5 – Related Party Transactions Office Lease – Laboratory Testing Services - Consulting –

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2022
Commitments and Contingencies
Commitments and Contingencies	NOTE 6 – Commitments and Contingencies Lease commitment – For the three months ended June 30, 2022 and 2021, the Company incurred rental expense in the amount of approximately $42,000 and 44,000, respectively. For the six months ended June 30, 2022 and 2021, the Company incurred rental expense in the amount of approximately $85,000 and 90,000, respectively.

Loss Per Share

Loss Per Share	6 Months Ended
Loss Per Share	Jun. 30, 2022
Loss Per Share
Loss Per Share	NOTE 7 – Loss Per Share For purposes of the diluted net income (loss) per share calculation, share options and warrants are considered to be potentially dilutive securities. Due to the Company’s net loss position and/or the share options and warrants having no intrinsic value, these potentially dilutive securities are excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive. Therefore, basic and diluted net income (loss) per share was the same for the periods presented in the unaudited Condensed Consolidated Statement of Comprehensive Loss. The following table shows the number of share equivalents that were excluded from the computation of diluted loss per share for the respective periods because the effect would have been anti-dilutive: Six Months Ended Six Months Ended June 30, 2022 June 30, 2021 Share options 379,811,585 123,449,035 Warrants 1,135,347,500 460,910,100 Restricted stock units 21,475,400 - Total Anti-Dilutive Share Equivalents 1,536,634,485 584,359,135

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2022
Subsequent Events
Subsequent Events	NOTE 8 – Subsequent Events On August 1, the Company announced that it is discontinuing the clinical program evaluating nomacopan in bullous pemphigoid (BP) and that Akari is now prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and to the pre-clinical program of PAS-nomacopan in geographic atrophy (GA). On September 12, 2022, the Company entered into securities purchase agreements with healthcare-focused institutional and accredited investors alongside participation from certain existing investors, including the Executive Chairman of the Board of Directors, Dr. Ray Prudo, providing for the issuance of an aggregate of 15,100,000 ADSs in a registered direct offering at $0.85 per ADS, resulting in gross proceeds of approximately $12.8 million. In addition, the Company issued to the investors unregistered series A warrants to purchase an aggregate of 15,100,000 ADSs and unregistered series B warrants to purchase up to an aggregate of 15,100,000 ADSs in a concurrent private placement. Series A and series B warrants will have an exercise price of $0.85 per ADS, will be exercisable immediately following the date of issuance and will expire two

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2022
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation –
Foreign Currency	Foreign Currency – The reporting currency of the Company is U.S. dollars. The Company translated its non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains/(losses).
Use of Estimates	Use of Estimates –
Fair Value Measurements	Fair Value Measurements
Cash	Cash –
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets
Property and Equipment, net	Property and Equipment, net – Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 3 Property and equipment, consists of the following: June 30, December 31, 2022 2021 Computers, peripheral, and scientific equipment $ 85,489 $ 85,489 Office furniture and equipment 79,449 79,449 Total property and equipment 164,938 164,938 Less: Accumulated depreciation (164,938) (164,938) Property and equipment, net $ - $ - The Company did not incur any depreciation expense for the three and six months ended June 30, 2022 and 2021.
Long-Lived Assets	Long-Lived Assets
Patent Acquisition Costs	Patent Acquisition Costs
Accrued Expenses	Accrued Expenses
Research and Development Expenses	Research and Development Expenses – Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations (CROs) and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. Research and development expenses for the three months ended June 30, 2022 and 2021 were $2,851,108 and $2,183,349, respectively. Research and development expenses for the six months ended June 30, 2022 and 2021 were $4,990,715 and $5,712,733, respectively. The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the Consolidated Statements of Comprehensive Loss.
Stock-Based Compensation Expense	Stock-Based Compensation Expense – Compensation - Stock Compensation
Leases	Leases –
Concentration of Credit Risk	Concentration of Credit Risk –
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with the accounting rules that require an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carryforwards and are measured using the expected tax rates estimated to be in effect when such basis differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized. The Company has recorded a full valuation allowance on its deferred tax assets as of June 30, 2022 and December 31, 2021.
Uncertain Tax Positions	Uncertain Tax Positions – Accounting for Uncertainty in Income Taxes Accounting for Uncertainty in Income Taxes
Earnings (Loss) Per Share	Earnings (Loss) Per Share
Comprehensive Loss	Comprehensive Loss – The following table provides details with respect to changes in accumulated other comprehensive loss, which is comprised of foreign currency translation adjustments, as presented in the balance sheets at June 30, 2022: Balance, January 1, 2022 $ (540,967) Net current period other comprehensive loss (80,590) Balance, June 30, 2022 $ (621,557)
Recent Accounting Pronouncements	Recent Accounting Pronouncements Adopted during the period – In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for convertible instruments by removing major separation models in ASC 470-20 that require separate accounting for embedded conversion features. ASU 2020-06 also removes certain settlement conditions in ASC 815-40 that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the scope exception and simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. Adoption of ASU 2020-06 can either be on a modified retrospective or full retrospective basis. The Company adopted this guidance effective January 1, 2022. The adoption of the guidance did not have a material impact on the consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
Summary of Significant Accounting Policies (Tables)	Jun. 30, 2022
Summary of Significant Accounting Policies
Schedule of estimated useful lives of the assets	Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 3
Schedule of components of property and equipment	June 30, December 31, 2022 2021 Computers, peripheral, and scientific equipment $ 85,489 $ 85,489 Office furniture and equipment 79,449 79,449 Total property and equipment 164,938 164,938 Less: Accumulated depreciation (164,938) (164,938) Property and equipment, net $ - $ -
Schedule of changes in accumulated other comprehensive loss	The following table provides details with respect to changes in accumulated other comprehensive loss, which is comprised of foreign currency translation adjustments, as presented in the balance sheets at June 30, 2022: Balance, January 1, 2022 $ (540,967) Net current period other comprehensive loss (80,590) Balance, June 30, 2022 $ (621,557)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2022
Class of Stock [Line Items]
Schedule of assumptions used for the fair value calculations	Below are the assumptions used for the fair value calculations of the warrants issued in 2021: July 16, 2021 Standard deviation 110.00 % Annual risk-free interest rate 0.79 % Required return on equity 17.00 % Expected life in years 4.98 Annual turnover rate 0.00 % Period risk-free rate 0.07 % NOTE 4 – Shareholders’ Equity (cont.) Below are the assumptions used for the fair value calculations of the warrants issued in 2022: January 4, March 10, 2022 2022 Expected dividend yield 0 % 0 % Expected volatility 110 % 110 % Risk-free interest 1.4 % 1.9 % Expected life 5.0 5.0

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
Shareholders' Equity (Tables)	Jun. 30, 2022
Class of Warrant or Right [Line Items]
Schedule of assumptions used for the fair value calculations	Below are the assumptions used for the fair value calculations of the warrants issued in 2021: July 16, 2021 Standard deviation 110.00 % Annual risk-free interest rate 0.79 % Required return on equity 17.00 % Expected life in years 4.98 Annual turnover rate 0.00 % Period risk-free rate 0.07 % NOTE 4 – Shareholders’ Equity (cont.) Below are the assumptions used for the fair value calculations of the warrants issued in 2022: January 4, March 10, 2022 2022 Expected dividend yield 0 % 0 % Expected volatility 110 % 110 % Risk-free interest 1.4 % 1.9 % Expected life 5.0 5.0
Schedule of Stockholders' Equity Note, Warrants or Rights	Balance Warrants Balance Warrants Balance Exercise December 31, Issued December 31, Issued June 30, Description Price 2020 in 2021 2021 in 2022 2022 2019 Investor Warrants $ 3.00 1,184,213 - 1,184,213 - 1,184,213 2019 Placement Warrants $ 2.85 177,629 - 177,629 - 177,629 2020 Investor Warrants $ 2.20 2,797,636 - 2,797,636 - 2,797,636 2020 Placement Warrants $ 2.55 449,623 - 449,623 - 449,623 July 2021 Placement Agent Warrants $ 2.32 - 398,384 398,384 - 398,384 December 2021 Investor Warrants $ 1.65 - - - 2,155,507 2,155,507 December 2021 Placement Agent Warrants $ 1.75 - - - 172,441 172,441 March 2022 Investor Warrants $ 1.40 - - - 3,720,409 3,720,409 March 2022 Placement Agent Warrants $ 1.50 - - - 297,633 297,633 4,609,101 398,384 5,007,485 6,345,990 11,353,475
Schedule of share option activity and related information for employees and directors	Weighted average Weighted Weighted remaining average average contractual Aggregate Number exercise grant date term intrinsic of shares price fair value (in years) value Options outstanding as of January 1, 2022 142,949,035 $ 0.07 6.8 - Changes during the period: Granted 253,134,400 $ 0.01 0.01 9.7 - Forfeited 16,271,850 $ 0.32 0.21 3.2 - Options outstanding at June 30, 2022 379,811,585 $ 0.02 8.7 - Exercisable options at June 30, 2022 93,802,185 $ 0.05 6.2 -
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	June 30, 2022 Expected dividend yield 0 % Expected volatility 72.8 - 90.4 % Risk-free interest 1.5% - 3.1 % Expected life 5.5-6.3 years
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	Weighted Remaining average Weighted contractual exercise average Weighted life (years price ($ Exercise remaining average for for price Options contractual exercise Options exercisable exercisable (range) ($) outstanding life (years) price ($) exercisable options) options) 0.01 244,634,400 9.7 0.01 - - - 0.02 101,950,000 7.7 0.02 60,575,000 7.1 0.02 0.03-0.05 14,450,000 5.2 0.04 14,450,000 5.2 0.04 0.12-0.32 18,777,185 3.8 0.16 18,777,185 3.8 0.16 379,811,585 93,802,185
Summary of activity of the Company's unvested RSUs	Weighted average grant date Intrinsic Shares/ fair value value Units per share per share Outstanding as of January 1, 2022 - - Changes during the period: Granted 21,475,400 $ 0.01 Vested - - Forfeited - - Outstanding at June 30, 2022 21,475,400 $ 253,410 $ 214,754

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
Loss Per Share (Tables)	Jun. 30, 2022
Loss Per Share
Schedule of Anti-Dilutive Share Equivalents	Six Months Ended Six Months Ended June 30, 2022 June 30, 2021 Share options 379,811,585 123,449,035 Warrants 1,135,347,500 460,910,100 Restricted stock units 21,475,400 - Total Anti-Dilutive Share Equivalents 1,536,634,485 584,359,135

Nature of Business (Details)

Nature of Business (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
Nature of Business (Details) - USD ($)	Jul. 07, 2021	Jun. 30, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Nature Of Business
accumulated deficit			$ 210,561,421		$ 210,561,421		$ 199,705,048
Cash			8,151,177		8,151,177		9,361,270
Net Cash Provided by (Used in) Operating Activities					13,623,341	$ 12,283,877
net loss			5,679,978	$ 4,346,335	10,856,373	$ 10,184,836
2020 Purchase Agreement
Nature Of Business
Gross proceeds from issuance	$ 12,300,000
Aspire Capital Fund LLC
Nature Of Business
Gross proceeds from issuance		$ 30,000,000					$ 2,000,001
Amount available under the share purchase commitment facility			22,000,000		22,000,000
Aspire Capital Fund LLC \| 2020 Purchase Agreement
Nature Of Business
Gross proceeds from issuance					$ 30,000,000			$ 6,000,000
Long-term purchase commitment period					30 months
Amount available under the share purchase commitment facility			$ 22,000,000		$ 22,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2020
Summary of Significant Accounting Policies [Line Items]
Total property and equipment	$ 164,938	$ 164,938
Less: Accumulated depreciation	$ (164,938)	(164,938)
Computers, peripheral, and scientific equipment
Summary of Significant Accounting Policies [Line Items]
Property, pant and equipment, useful life	3 years
Total property and equipment	$ 85,489	85,489
Office furniture and equipment
Summary of Significant Accounting Policies [Line Items]
Property, pant and equipment, useful life	3 years
Total property and equipment	$ 79,449	$ 79,449

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Comprehensive Loss (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Summary of Significant Accounting Policies [Line Items]
Beginning Balance			$ (540,967)
Net current period other comprehensive loss	$ (48,240)	$ (78,118)	(80,590)	$ 227,979
Ending Balance	$ (621,557)		$ (621,557)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Summary of Significant Accounting Policies [Line Items]
Cash equivalents	$ 0		$ 0		$ 0
Prepaid expenses	3,085,898		3,085,898		2,173,528
Research and Development expenses	2,851,108	$ 2,183,349	4,990,715	$ 5,712,733
Depreciation	0	0	0	0
Unrecognized tax benefits	0		$ 0		$ 0
Patents
Summary of Significant Accounting Policies [Line Items]
Finite-Lived intangible assets, remaining amortization period			22 years
Amortization of intangible assets	$ 942	$ 1,048	$ 1,948	$ 2,082

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)						1 Months Ended	6 Months Ended	12 Months Ended
Fair Value Measurements - Additional Information (Details)	Mar. 10, 2022 USD ($) $ / shares shares	Jan. 04, 2022 USD ($) $ / shares shares	Dec. 29, 2021 USD ($) $ / shares shares	Jul. 16, 2021 D	Jul. 07, 2021 shares	Jul. 31, 2021 USD ($) $ / shares	Jun. 30, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares	Dec. 31, 2020 shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate ADSs issued (in shares)					7,947,529
Threshold consecutive trading day period to call for exercise of warrants \| D				10
Nominal value of ADS (in per warrant ADS) \| $ / shares							$ 0.0001	$ 0.0001
Warrants Issued							6,345,990	398,384
Warrants outstanding (in shares)							11,353,475	5,007,485	4,609,101
Placement agent warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Placement agent fees and expenses \| $	$ 297,633
Registered Direct Offering
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate ADSs issued (in shares)			4,311,019
Share issue price (in dollars per ADS) \| $ / shares			$ 1.40
Gross proceeds from issuance \| $	$ 8,900,000		$ 6,000,000
Warrants issued to purchase ADS (in shares).							2,327,948
Nominal value of ADS (in per warrant ADS) \| $ / shares							$ 0.0001
Registered Direct Offering \| Investor warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued to purchase ADS (in shares).	3,720,409
Exercise price of warrants (in dollars per ADS) \| $ / shares	$ 1.40
Registered Direct Offering \| Placement agent warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued to purchase ADS (in shares).		172,441
Exercise price of warrants (in dollars per ADS) \| $ / shares	$ 1.50	$ 1.75
Placement agent fees and expenses \| $	$ 774,320	$ 542,834
Private Placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued to purchase ADS (in shares).							398,384
Placement agent fees and expenses \| $						$ 993,000
Threshold period for exercise of warrants on cashless basis						9 months
Nominal value of ADS (in per warrant ADS) \| $ / shares							$ 0.0001
Warrants Issued							4,018,042
Private Placement \| Investor warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price of warrants (in dollars per ADS) \| $ / shares			$ 1.65
Private Placement \| Placement agent warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price of warrants (in dollars per ADS) \| $ / shares						$ 3

Shareholders' Equity - Assumpti

Shareholders' Equity - Assumptions used for the fair value calculations of the warrants (Details) - July 2021 warrants	Jul. 16, 2021
Standard deviation
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	110
Annual risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.79
Required return on equity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	17
Expected life in years
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	4.98
Annual turnover rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0
Period risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.07

Shareholders' Equity - Assump_2

Shareholders' Equity - Assumptions used for the fair value calculation of the warrants issued 2022 (Details)			6 Months Ended
	Mar. 10, 2022	Jan. 04, 2022	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0%	0%	0%
Expected volatility	110%	110%
Risk-free interest	1.90%	1.40%
Expected life	5 years	5 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			72.80%
Risk-free interest			1.50%
Expected life			5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			90.40%
Risk-free interest			3.10%
Expected life			6 years 3 months 18 days

Shareholders' Equity - Warrants

Shareholders' Equity - Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
Shareholders' Equity - Warrants (Details) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Beginning Balance	5,007,485	4,609,101
Warrants Issued	6,345,990	398,384
Ending Balance	11,353,475	5,007,485
2019 Investor Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 3
Beginning Balance	1,184,213	1,184,213
Ending Balance	1,184,213	1,184,213
2019 Placement Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.85
Beginning Balance	177,629	177,629
Ending Balance	177,629	177,629
2020 Investor Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.20
Beginning Balance	2,797,636	2,797,636
Ending Balance	2,797,636	2,797,636
2020 Placement Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.55
Beginning Balance	449,623	449,623
Ending Balance	449,623	449,623
July 2021 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.32
Beginning Balance	398,384
Warrants Issued		398,384
Ending Balance	398,384	398,384
December 2021 Investor Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 1.65
Warrants Issued	2,155,507
Ending Balance	2,155,507
December 2021 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 1.75
Warrants Issued	172,441
Ending Balance	172,441
March 2022 Investor Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 1.40
Warrants Issued	3,720,409
Ending Balance	3,720,409
March 2022 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Exercise Price	$ 1.50
Warrants Issued	297,633
Ending Balance	297,633

Shareholders' Equity - Stock op

Shareholders' Equity - Stock option activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Options Outstanding at beginning of the period	142,949,035
Number of shares, Granted	253,134,400
Number of shares, Forfeited	16,271,850
Number of shares, Options Outstanding at end of the period	379,811,585	142,949,035
Number of shares, Exercisable options at end of the period	93,802,185
Weighted average exercise price, Outstanding at beginning of the period	$ 0.07
Weighted average exercise price, Granted	0.01
Weighted average exercise price, Forfeited	0.32
Weighted average exercise price, Outstanding at end of the period	0.02	$ 0.07
Options exercisable at end of the period, Weighted average exercise price	0.05
Weighted average grant date fair value, Granted	0.01
Weighted average grant date fair value, Forfeited	$ 0.21
Weighted average remaining contractual term, Options outstanding during the period (in years)	8 years 8 months 12 days	6 years 9 months 18 days
Weighted average remaining contractual term, Granted during the period (in years)	9 years 8 months 12 days
Weighted average remaining contractual term, Forfeited during the period (in years)	3 years 2 months 12 days
Weighted average remaining contractual term, Options exercisable at end of the period (in years)	6 years 2 months 12 days

Shareholders' Equity - Option e

Shareholders' Equity - Option exercise price (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	379,811,585	142,949,035
Weighted average remaining contractual life (years)	8 years 8 months 12 days	6 years 9 months 18 days
Weighted average exercise Price	$ 0.02	$ 0.07
Options exercisable	93,802,185
Remaining contractual life (years for exercisable options)	6 years 2 months 12 days
Weighted average exercise price (for exercisable options)	$ 0.05
Exercise Price Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (range)	$ 0.01
Options outstanding	244,634,400
Weighted average remaining contractual life (years)	9 years 8 months 12 days
Weighted average exercise Price	$ 0.01
Exercise Price Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (range)	$ 0.02
Options outstanding	101,950,000
Weighted average remaining contractual life (years)	7 years 8 months 12 days
Weighted average exercise Price	$ 0.02
Options exercisable	60,575,000
Remaining contractual life (years for exercisable options)	7 years 1 month 6 days
Weighted average exercise price (for exercisable options)	$ 0.02
Exercise Price Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	14,450,000
Weighted average remaining contractual life (years)	5 years 2 months 12 days
Weighted average exercise Price	$ 0.04
Options exercisable	14,450,000
Remaining contractual life (years for exercisable options)	5 years 2 months 12 days
Weighted average exercise price (for exercisable options)	$ 0.04
Exercise Price Range Three \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (range)	0.03
Exercise Price Range Three \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (range)	$ 0.05
Exercise price range four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	18,777,185
Weighted average remaining contractual life (years)	3 years 9 months 18 days
Weighted average exercise Price	$ 0.16
Options exercisable	18,777,185
Remaining contractual life (years for exercisable options)	3 years 9 months 18 days
Weighted average exercise price (for exercisable options)	$ 0.16
Exercise price range four \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (range)	0.12
Exercise price range four \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (range)	$ 0.32

Shareholders' Equity - Summariz

Shareholders' Equity - Summarize the activity of the company unvested RSUs (Details) - Restricted stock units	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Shares/ Units
Granted (in shares) \| shares	21,475,400
Outstanding at end of the period (in shares) \| shares	21,475,400
Weighted average grant date fair value per share
Granted (per share) \| $ / shares	$ 0.01
Weighted average grant date fair value per share, End of the period (per share) \| $ / shares	$ 253,410
Intrinsic value per share
Intrinsic value per share, Outstanding \| $	$ 214,754

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Mar. 10, 2022 USD ($) $ / shares shares

Jan. 04, 2022 USD ($) $ / shares shares

Dec. 29, 2021 USD ($) $ / shares shares

Jul. 16, 2021 USD ($) D $ / shares shares

Jul. 07, 2021 USD ($) $ / shares shares

Jul. 31, 2021 USD ($) $ / shares

Jun. 30, 2020 USD ($) $ / shares shares

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2021 USD ($) $ / shares

Jun. 30, 2022 USD ($) D item $ / shares shares

Jun. 30, 2021 USD ($) $ / shares

Jun. 30, 2020 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) $ / shares shares

Dec. 31, 2020 USD ($) shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of Ordinary Shares Representing One American Depositary Share | shares

100

Stock Issued During Period, Shares, New Issues | shares

7,947,529

Gross proceeds | $

$ 12,366,469

$ 1,993,529

Threshold consecutive trading day period to call for exercise of warrants | D

Nominal value of ADS (in per warrant ADS) | $ / shares

$ 0.0001

Warrants Issued | shares

6,345,990

398,384

2020 Purchase Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Gross proceeds from issuance | $

$ 12,300,000

Sale of Stock, Price Per Share | $ / shares

$ 1.55

Investor warrants | 2020 Purchase Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued to purchase ADS (in shares) | shares

398,384

Exercise price of warrants (in dollars per ADS) | $ / shares

$ 2.32

Placement agent warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Placement agent fees and expenses | $

$ 297,633

July 2021 warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expiration term of warrants

5 years

Fair value of warrants | $

$ 231,063

December 2021 warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expiration term of warrants

5 years

Fair value of warrants | $

$ 2,605,577

March 2022 warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expiration term of warrants

5 years

Fair value of warrants | $

$ 3,693,622

Aspire Capital Fund LLC

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Gross proceeds from issuance | $

$ 30,000,000

$ 2,000,001

Number of Shares to be Issued | shares

117,647,100

Percentage Of Volume Weighted Average Price Indicating Purchase Price

97%

Stock Issued During Period, Shares, New Issues | shares

40,760,900

Gross proceeds | $

$ 30,000,000

Amount available under the share purchase commitment facility | $

$ 22,000,000

22,000,000

Aspire Capital Fund LLC | 2020 Purchase Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Gross proceeds from issuance | $

$ 30,000,000

$ 6,000,000

Long-term purchase commitment period

30 months

Sale of Stock, Price Per Share | $ / shares

$ 1.20

Stock Issued During Period, Shares, New Issues | shares

460,758,800

Amount available under the share purchase commitment facility | $

22,000,000

$ 22,000,000

Warrants issued to purchase ADS (in shares) | shares

7,440,833

Fair value of commitment shares | $

$ 900,000

American Depositary Share | 2020 Purchase Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Arithmetic average number of lowest closing prices for purchase of ADSs | item

Threshold consecutive business days | D

American Depositary Share | Aspire Capital Fund LLC

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Gross proceeds from issuance | $

$ 30,000,000

Number of Shares to be Issued | shares

150,000

Sale of Stock, Description of Transaction

30% of the aggregate shares of the Company’s ADSs traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of 250,000 ADSs

Sale of Stock, Price Per Share | $ / shares

$ 0.25

Share issue price (in dollars per ADS) | $ / shares

$ 0.0001

Non Employee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized | $

$ 2,619,879

Employee service share based compensation, non vested awards, compensation cost not yet recognized, period for recognition

3 years 6 months

Registered Direct Offering

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Gross proceeds from issuance | $

$ 8,900,000

$ 6,000,000

Sale of Stock, Price Per Share | $ / shares

$ 1.40

Stock Issued During Period, Shares, New Issues | shares

4,311,019

Warrants issued to purchase ADS (in shares) | shares

2,327,948

Nominal value of ADS (in per warrant ADS) | $ / shares

$ 0.0001

Registered Direct Offering | Investor warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued to purchase ADS (in shares) | shares

3,720,409

Exercise price of warrants (in dollars per ADS) | $ / shares

$ 1.40

Registered Direct Offering | Placement agent warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued to purchase ADS (in shares) | shares

172,441

Exercise price of warrants (in dollars per ADS) | $ / shares

$ 1.50

$ 1.75

Placement agent fees and expenses | $

$ 774,320

$ 542,834

Private Placement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued to purchase ADS (in shares) | shares

398,384

Nominal value of ADS (in per warrant ADS) | $ / shares

$ 0.0001

Placement agent fees and expenses | $

$ 993,000

Threshold period for exercise of warrants on cashless basis

9 months

Warrants Issued | shares

4,018,042

Private Placement | Paulson Warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued to purchase ADS (in shares) | shares

2,155,507

Private Placement | Investor warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price of warrants (in dollars per ADS) | $ / shares

$ 1.65

Private Placement | Placement agent warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price of warrants (in dollars per ADS) | $ / shares

$ 3

Employees And Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, Share-based Compensation, Gross | $

$ 122,856

$ 82,102

$ 221,692

$ 166,994

2014 Equity Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise of options (in shares) | shares

890,000,000

Share based compensation arrangement by share based payment award, number of additional shares authorized | shares

510,188,415

Share based compensation arrangement by Share based payment award, expiration period

10 years

2014 Equity Incentive Plan | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation arrangement by Share based payment award, award vesting period

1 year

2014 Equity Incentive Plan | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation arrangement by Share based payment award, award vesting period

4 years

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
Related Party Transactions (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
The Doctors Laboratory
Related Party Transaction [Line Items]
Operating Lease, Expense	$ 33,000	$ 37,000	$ 67,000	$ 75,000
Consulting Service
Related Party Transaction [Line Items]
Expenses from transactions with related party	25,000	25,000	50,000	50,000
Laboratory Testing Services
Related Party Transaction [Line Items]
Outstanding accounts payables	28,000	69,000	28,000	69,000
Expenses from transactions with related party	$ 5,000	$ 19,000	$ 9,000	$ 90,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		6 Months Ended
Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Loss Contingencies [Line Items]
Rental expense	$ 42,000	$ 44,000	$ 85,000	$ 90,000

Loss Per Share - Shares exclude

Loss Per Share - Shares excluded from computation (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Line Items]
Total Anti-Dilutive Share Equivalents	1,536,634,485	584,359,135
Share options
Earnings Per Share [Line Items]
Total Anti-Dilutive Share Equivalents	379,811,585	123,449,035
Warrants Equity Classified
Earnings Per Share [Line Items]
Total Anti-Dilutive Share Equivalents	1,135,347,500	460,910,100
Restricted stock units
Earnings Per Share [Line Items]
Total Anti-Dilutive Share Equivalents	21,475,400

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)						1 Months Ended
Subsequent Events (Details) - USD ($)	Sep. 12, 2022	Mar. 10, 2022	Jan. 04, 2022	Dec. 29, 2021	Jul. 07, 2021	Jul. 31, 2021	Jun. 30, 2022
Subsequent Events
Aggregate ADSs issued (in shares)					7,947,529
Placement agent warrants
Subsequent Events
Placement agent fees and expenses		$ 297,633
Registered Direct Offering
Subsequent Events
Aggregate ADSs issued (in shares)				4,311,019
Gross proceeds		$ 8,900,000		$ 6,000,000
Share issue price (in dollars per ADS)				$ 1.40
Warrants issued to purchase ADS (in shares).							2,327,948
Registered Direct Offering \| Investor warrants
Subsequent Events
Warrants issued to purchase ADS (in shares).		3,720,409
Exercise price of warrants (in dollars per ADS)		$ 1.40
Registered Direct Offering \| Placement agent warrants
Subsequent Events
Warrants issued to purchase ADS (in shares).			172,441
Exercise price of warrants (in dollars per ADS)		$ 1.50	$ 1.75
Placement agent fees and expenses		$ 774,320	$ 542,834
Private Placement
Subsequent Events
Warrants issued to purchase ADS (in shares).							398,384
Placement agent fees and expenses						$ 993,000
Private Placement \| Investor warrants
Subsequent Events
Exercise price of warrants (in dollars per ADS)				$ 1.65
Private Placement \| Placement agent warrants
Subsequent Events
Exercise price of warrants (in dollars per ADS)						$ 3
Subsequent Events. \| Registered Direct Offering \| Investor warrants
Subsequent Events
Exercise price of warrants (in dollars per ADS)	$ 0.85
Subsequent Events. \| Registered Direct Offering \| Placement agent warrants
Subsequent Events
Placement agent fees and expenses	$ 1,026,000
Subsequent Events. \| Registered Direct Offering \| Series A warrants
Subsequent Events
Expiration term of warrants	2 years
Subsequent Events. \| Registered Direct Offering \| Series B warrants
Subsequent Events
Expiration term of warrants	7 years
Subsequent Events. \| Registered Direct Offering \| American Depositary Share
Subsequent Events
Aggregate ADSs issued (in shares)	15,100,000
Share issue price (in dollars per ADS)	$ 0.85
Gross proceeds	$ 12,800,000
Subsequent Events. \| Private Placement \| American Depositary Share
Subsequent Events
Share issue price (in dollars per ADS)	$ 0.85
Subsequent Events. \| Private Placement \| American Depositary Share \| Series A warrants
Subsequent Events
Warrants issued to purchase ADS (in shares).	15,100,000
Subsequent Events. \| Private Placement \| American Depositary Share \| Series B warrants
Subsequent Events
Warrants issued to purchase ADS (in shares).	15,100,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Property and equipment, net (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2020
Summary of Significant Accounting Policies [Line Items]
Total property and equipment	$ 164,938	$ 164,938
Less: Accumulated depreciation	$ (164,938)	(164,938)
Computers, peripheral, and scientific equipment
Summary of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Total property and equipment	$ 85,489	85,489
Office furniture and equipment
Summary of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Total property and equipment	$ 79,449	$ 79,449

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Textual (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Summary of Significant Accounting Policies [Line Items]
Depreciation	$ 0	$ 0	$ 0	$ 0
Research and Development Expense	2,851,108	2,183,349	4,990,715	5,712,733
Unrecognized Tax Benefits	0		$ 0		$ 0
Patents
Summary of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period			22 years
Amortization of Intangible Assets	$ 942	$ 1,048	$ 1,948	$ 2,082